title: Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
authors.affiliation: Service d'Hématologie, Hôpital Edouard Herriot, 69437, Lyon Cedex 03, France. xavier.thomas@chu-lyon.fr
authors.forename: Xavier
authors.initials: X
authors.lastname: Thomas
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Boiron
authors.forename: Françoise
authors.initials: F
authors.lastname: Huguet
authors.forename: Oumedaly
authors.initials: O
authors.lastname: Reman
authors.forename: Laurent
authors.initials: L
authors.lastname: Sutton
authors.forename: Pascal
authors.initials: P
authors.lastname: Turlure
authors.forename: Frédéric
authors.initials: F
authors.lastname: Garban
authors.forename: Claude
authors.initials: C
authors.lastname: Gardin
authors.forename: Daniel
authors.initials: D
authors.lastname: Espinouse
authors.forename: Olivier
authors.initials: O
authors.lastname: Boulat
authors.forename: Véronique
authors.initials: V
authors.lastname: Lhéritier
authors.forename: Denis
authors.initials: D
authors.lastname: Fiere
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005334:Fever / Q000209:etiology; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D017053:Infection Control; D007239:Infections / Q000453:epidemiology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D009504:Neutrophils / Q000187:drug effects*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D012074:Remission Induction; D016879:Salvage Therapy; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000900:Anti-Bacterial Agents; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D011241:Prednisone; D015255:Idarubicin; D003630:Daunorubicin